Fever Dream

Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening

Retrieved on: 
Thursday, April 4, 2024
Certification, Plasma, CE, GRFS, Risk, Arbovirus, Climate, RNA, GRF, Fever Dream, IVDR, Chikungunya, Death, Dengue virus, MCE, Blood bank, NAT, Vertically transmitted infection, Medical device

These are the four most significant arboviruses of concern, all spread through mosquito vectors.

Key Points: 
  • These are the four most significant arboviruses of concern, all spread through mosquito vectors.
  • With the dengue virus alone, there were more than 5 million cases and 5,000 deaths reported globally in 2023.1
    Further strengthening the Grifols Procleix portfolio for blood donor screening, the Procleix ArboPlex Assay uses plasma or serum samples to detect arboviral RNA.
  • Blood banks and collection centers could decide that deferrals are unnecessary if donors were tested and found negative using the Procleix ArboPlex Assay.
  • “With its 4-in-1 arbovirus test feature, the Grifols Procleix ArboPlex Assay has the ability to speed up and overall improve donor screening laboratory efficiency,” said Antonio Martínez, president of Grifols Diagnostic Business Unit.

Kao and Earth Collaborate in the Field of “Insect (Mosquito) Control” in Thailand

Retrieved on: 
Thursday, February 29, 2024
Infectious Diseases, Other Health, Other Retail, Health, Retail, Ministry, Multimedia, ARS, Viral disease, Public health, Urbanization, Life, Learning, Climate, School, Dengue fever, Death, Fever Dream, Corporation, Kao Corporation, Research, Vaccine

It will be launched in Thailand from July 2024, where Earth has been active domestically for about 40 years.

Key Points: 
  • It will be launched in Thailand from July 2024, where Earth has been active domestically for about 40 years.
  • Earth Corporation founded ARS Chemical (Thailand) Co., Ltd. (now Earth (Thailand) Co., Ltd.) in Thailand in 1980.
  • Earth (Thailand) single-handedly manages development, sales and distribution of, for example, the insect control item brand ARS as a local subsidiary in Thailand.
  • Both Kao and Earth believe that this product will help people living in areas suffering from dengue fever.

Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas

Retrieved on: 
Tuesday, February 27, 2024
Medical Supplies, Health, Infectious Diseases, Other Health, Pharmaceutical, Biotechnology, Immunization, Infection, Multimedia, Dengue fever, Biological E. Limited, Urbanization, Vaccine, Risk, History, Fever Dream, Public, Biology, Pharmaceutical industry, Travel, Partnership

Takeda ( TSE:4502/NYSE:TAK ) and Biological E. Limited (BE), a leading India-based Vaccines and Pharmaceutical Company, today announced a strategic partnership to accelerate access to QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003) multi-dose vials (MDVs).

Key Points: 
  • Takeda ( TSE:4502/NYSE:TAK ) and Biological E. Limited (BE), a leading India-based Vaccines and Pharmaceutical Company, today announced a strategic partnership to accelerate access to QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003) multi-dose vials (MDVs).
  • These doses will ultimately be made available for procurement by governments in endemic countries by 2030 at the latest to support National Immunization Programs.
  • MDVs offer economic and logistical advantages for National Immunization Programs by minimizing packaging and storage expenses, while also reducing medical and environmental waste.
  • Together, we will help combat dengue on a global scale by significantly increasing manufacturing capacity for multi-dose vials of QDENGA to drive sustainable access to the vaccine in more endemic countries."

Co-Diagnostics, Inc. JV CoSara Receives Clearance from Indian Regulators for Influenza Multiplex PCR Test

Retrieved on: 
Thursday, March 7, 2024
Influenza, Hepatitis B, CDSCO, FDA, Point-of-care testing, Growth, 2005 in television, Sale, ABC, Euro starter kits, Malaria, COVID-19, Fever Dream, RT, Mycobacterium tuberculosis, HPV, Chikungunya, PCR, Hepatitis C, IVD, Vaccine

SALT LAKE CITY, March 7, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara Diagnostics Pvt Ltd ("CoSara," or the "JV"), its joint venture for manufacturing and sales in India, has received clearance by the Central Drugs Standard Control Organization ("CDSCO") in India to manufacture and sell its SARAPLEX™ Influenza Multiplex (IFM) Test Kit to clinical laboratories as an in vitro diagnostic ("IVD") for the detection and differentiation of Influenza A and Influenza B.

Key Points: 
  • Co-Primers utilize a unique design architecture to combat common issues with real-time PCR that can lead to inaccurate results, specifically primer dimer propagation, and which are magnified in multiplex reactions.
  • "The importance of accurate, reliable PCR testing at the high-throughput clinical laboratory level remains critical," remarked Dwight Egan, CEO of Co-Diagnostics.
  • *The Co-Dx PCR platform (including the PCR Home™, PCR Pro™, mobile app, and all associated tests) is subject to review by the FDA and/or other regulatory bodies and is not yet available for sale.
  • The Co-Dx PCR Pro instrument and Co-Dx COVID-19 Test are currently under review by the FDA.

Warm Weather Trends Signal Potential Upswing in Disease-Carrying Pests

Retrieved on: 
Tuesday, February 20, 2024
Senior, Weather, Tick, Lyme disease, Growth, Raleigh, North Carolina, Rat, Freezing, NPMA, Cockroach, Health, National Pest Management Association, Biting, Mouse, City, Virus, Fever Dream, Vector, Public affairs, CDC, Human, Water, Infection, Vaccine

FAIRFAX, Va., Feb. 20, 2024 /PRNewswire/ -- Today, the National Pest Management Association (NPMA) presents its bi-annual Vector Sectors™ list, unveiling the top 10 U.S. cities at heightened risk for increased vector pest pressure throughout the remainder of winter and into spring.

Key Points: 
  • "With springtime and warm weather on the horizon, many Americans are itching to get outside," said Dr. Jim Fredericks, Senior Vice President of Public Affairs for NPMA.
  • "Some pests can leave more than an itchy bite mark," said Dr. Jorge Parada, Medical Advisor for NPMA with a focus on infectious disease.
  • "Vector pests can spread pathogens to humans through their bites, making prevention especially important to help reduce transmission of dangerous and potentially deadly diseases."
  • For more information on NPMA's Vector Sectors list and to learn more about protecting against vector pests, visit PestWorld.org .

Global Research Antibodies Market Report 2024, Featuring Profiles of Abcam, Thermo Fisher Scientific, Cell Signaling Technology, Merck, Sino Biological & Bio-Rad - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 31, 2024
Biotechnology, Infectious Diseases, Health, Science, Research, Antigen, Growth, Bio-Rad Laboratories, ESG, Fever Dream, Therapy, HIV, Thermo Fisher Scientific, Antibody, FDA, Microscopy, IVD, Abcam, Infection, Flow cytometry, Malaria, Merck Group, Vaccine

The global market for research antibodies was valued at approximately $3.5 billion in 2022.

Key Points: 
  • The global market for research antibodies was valued at approximately $3.5 billion in 2022.
  • Among product segments, the primary antibody segment accounted for the highest market share in the global market for research antibodies in 2022.
  • The advancement of biological discoveries will result in the need for more molecular targets to be detected by their antibodies.
  • This report segments the global market for research antibodies based on type of antibody, clonality, host, major reactivities, application, end user and region.

The Astellas Global Health Foundation Provides $2.6 Million in New Funding to Address Urgent Health Needs in Africa, South America, and the Middle East

Retrieved on: 
Thursday, January 25, 2024
Weather, Mortality, Woman, Health, Plan International, Food, PATH, TB, Goal 3, Tuberculosis, Success, Capacity building, Policy, Mental health, Fever Dream, Organization, Plan, Disaster, Risk, COVID-19, HIV/AIDS, Amref Health Africa, AMPATH, Immunization, Child, International Medical Corps, Malaria, Climate, Mestizo, Substance abuse, African, Community resilience

The selected organizations -- International Medical Corps, PATH, and Plan International -- are expected to use the Foundation grants to impact nearly 750,000 lives combined over the next three years. This latest funding, in addition to active grants in progress with Amref Health Africa and AMPATH Kenya, reinforces the Foundation's objective to help high-need populations within low- and middle-income countries where Astellas does not have a business presence.

Key Points: 
  • Efforts will include strengthening healthcare infrastructure and building resilience in 10 vulnerable and hard-to-reach Yemeni communities (projected impact: more than 60,000 lives).
  • In 2020 and 2021, the Foundation supported the organization's important work fighting COVID-19 in Nigeria and malaria and dengue in Venezuela.
  • PATH: The Foundation has awarded a three-year grant of more than $1.6 million to help PATH address HIV/AIDS and tuberculosis (TB) healthcare delivery barriers in Kenya.
  • The grant will also see supply chain strengthening activities to ensure the availability of high-quality commodities and tools for community health units.

Staying Hydrated: QNET's Solution to Keeping Your New Year's Resolutions

Retrieved on: 
Tuesday, January 23, 2024
Diarrhea, Filter, World Health Organization, Taste, Weight loss, Health, Face, Water quality, Sanitation, Fever Dream, Dysentery, Water purification, Water, Bacteria, Guilt, QNET, Virus, Lethargy, Exercise, Cholera, Absorption, Motivation, Hepatitis A

Yet, a startling statistic reveals that by February, about 80% of these resolutions fall by the wayside.

Key Points: 
  • Yet, a startling statistic reveals that by February, about 80% of these resolutions fall by the wayside.
  • Studies show that staying well-hydrated aids in weight loss by enhancing satiety, boosts metabolism, and helps in reducing water retention.
  • More than just aiding in weight management, proper hydration is essential for maintaining energy levels, improving physical performance, and sharpening cognitive functions.
  • As we navigate our resolutions, understanding the role of hydration in our daily lives is key.

Therapeutic Vaccines Market Size and Share to Surpass USD 87 Billion by 2035 - Exclusive Report by Roots Analysis

Retrieved on: 
Tuesday, January 9, 2024
Neurological disorder, Patient, Therapy, Research, Cancer, Glioblastoma, ALS, DNA, Epidemic, Tuberculosis, VB, Myeloid leukemia, Lung cancer, Bill, Fever Dream, Infection, Hepatocellular carcinoma, Immune system, Combination therapy, Epstein–Barr virus, Cervical cancer, California Institute of Technology, Intrathecal administration, HIV, Complex, Malaria, Organization, Merck, Vaccine, Colorectal cancer, OPKO Health, Roche, Anal cancer, Prevalence, Growth, Pharmaceutical industry

LONDON, Jan. 9, 2024 /PRNewswire/ -- The global therapeutic vaccines market is estimated to be worth USD 2 billion in 2023 and is anticipated to reach USD 87 billion by 2035. It is expected to grow at a compounded annual growth rate (CAGR) of 35% during the forecast period from 2023 to 2035.

Key Points: 
  • The therapeutic vaccines market is also driven by the expanding pipeline of therapeutic vaccine candidates in the clinical development stages.
  • Based on the type of vaccine, the therapeutic vaccines market is segmented into antigen vaccines, dendritic vaccines, DNA vaccines, and peptide vaccines.
  • Based on the type of method of vaccine composition, the therapeutic vaccines market is segmented into autologous vaccines, allogeneic vaccines and other methods.
  • Europe will dominate the therapeutic vaccines market and is anticipated to capture 59% of the overall revenue share in 2023.

Therapeutic Vaccines Market Size and Share to Surpass USD 87 Billion by 2035 - Exclusive Report by Roots Analysis

Retrieved on: 
Tuesday, January 9, 2024
Neurological disorder, Patient, Therapy, Research, Cancer, Glioblastoma, ALS, DNA, Epidemic, Tuberculosis, VB, Myeloid leukemia, Lung cancer, Bill, Fever Dream, Infection, Hepatocellular carcinoma, Immune system, Combination therapy, Epstein–Barr virus, Cervical cancer, California Institute of Technology, Intrathecal administration, HIV, Complex, Malaria, Organization, Merck, Vaccine, Colorectal cancer, OPKO Health, Roche, Anal cancer, Prevalence, Growth, Pharmaceutical industry

LONDON, Jan. 9, 2024 /PRNewswire/ -- The global therapeutic vaccines market is estimated to be worth USD 2 billion in 2023 and is anticipated to reach USD 87 billion by 2035. It is expected to grow at a compounded annual growth rate (CAGR) of 35% during the forecast period from 2023 to 2035.

Key Points: 
  • The therapeutic vaccines market is also driven by the expanding pipeline of therapeutic vaccine candidates in the clinical development stages.
  • Based on the type of vaccine, the therapeutic vaccines market is segmented into antigen vaccines, dendritic vaccines, DNA vaccines, and peptide vaccines.
  • Based on the type of method of vaccine composition, the therapeutic vaccines market is segmented into autologous vaccines, allogeneic vaccines and other methods.
  • Europe will dominate the therapeutic vaccines market and is anticipated to capture 59% of the overall revenue share in 2023.